Background: In 1999, the United Kingdom (UK) was the first country to introduce meningococcal group C (MenC) conjugate vaccination. This vaccination programme has evolved with further understanding, new vaccines and changing disease epidemiology. Aim: To characterise MenC disease and population protection against MenC disease in England. Methods: Between 1998/99–2015/16, surveillance data from England for laboratory-confirmed MenC cases were collated; using the screening method, we updated vaccine effectiveness (VE) estimates. Typing data and genomes were obtained from the Meningitis Research Foundation Meningococcus Genome Library and PubMLST database. Phylogenetic network analysis of MenC cc11 isolates was undertaken. We compared bactericidal antibody assay results using anonymised sera from 2014 to similar data from 1996–1999, 2000–2004 and 2009. Results: MenC cases fell from 883 in 1998/99 (1.81/100,000 population) to 42 cases (0.08/100,000 population) in 2015/16. Lower VE over time since vaccination was observed after infant immunisation (p = 0.009) and a single dose at 1–4 years (p = 0.03). After vaccination at 5–18 years, high VE was sustained for 8 years; 95.0% (95% CI: 76.0–99.5%). Only 25% (75/299) children aged 1–14 years were seroprotected against MenC disease in 2014. Recent case isolates mostly represented two cc11 strains. Conclusion: High quality surveillance has furthered understanding of MenC vaccines and improved schedules, maximising population benefit. The UK programme provides high direct and indirect protection despite low levels of seroprotection in some age groups. High-resolution characterisation supports ongoing surveillance of distinct MenC cc11 lineages.

Introduction

Neisseria meningitidis is a major cause of meningitis and septicaemia worldwide. Efforts to control meningococcal disease have been aimed at the development of effective vaccines and subsequent implementation in appropriate immunisation schedules. Twelve different meningococcal serogroups are recognised and serogroup B (MenB) is currently responsible for most cases of invasive meningococcal disease (IMD) in Europe. Many countries, including the United Kingdom (UK), experienced large outbreaks of serogroup C (MenC) disease in the mid-1990s, due mainly to the ST-11 clonal complex (cc11) [1]. In 1999, the UK became the first country to introduce the MenC conjugate (MCC) vaccine in a phased national campaign targeting all those aged less than 18 years over a 12-month period, alongside a routine three-dose infant programme [2]. Vaccine eligibility was later extended up to 24 years of age, although this age group was not actively called for vaccination. Routine use of MCC vaccine in many other European countries followed [3].

As MCC vaccines were licensed on immunogenicity studies alone, without direct evidence of clinical efficacy, comprehensive national surveillance was initiated concurrently in order to monitor the vaccines’ impact in a population-based setting [2]. MCC vaccination was associated with rapid and sustained declines in MenC disease across all age groups through direct and indirect (herd/population) protection [3-5]. Invasive disease is rare following nasopharyngeal acquisition where the meningococcus can persist for several months before it is cleared; this asymptomatic carriage, especially in older teenagers, is an important reservoir for infection, onward transmission to
susceptible individuals and immunity. In the UK, there was a 66% reduction in MenC carriage among 15–19 year-olds within 1 year of MCC vaccine implementation and this reduction was key to establishing indirect protection across the population [6].

The UK MCC immunisation programme has evolved over time (Box) and, from 2013, has included an adolescent MCC vaccine programme to extend direct protection in teenagers and maintain indirect protection in the wider population. In 2015, this vaccine was replaced with the quadrivalent meningococcal conjugate vaccine (MenACWY) to combat a national MenW outbreak. A multi-component, protein-based vaccine against MenB was also implemented in the infant immunisation schedule at the same time [7]. In July 2016, the infant MCC dose was removed because MenC cases were extremely rare in this age group and population protection was likely to be maintained through the adolescent MenACWY programme.

**Methods**

**National epidemiology**

Public Health England (PHE) conducts enhanced national surveillance of IMD in England. The PHE Meningococcal Reference Unit (MRU) provides a national service for confirming, grouping and characterising invasive meningococcal isolates [11]. The MRU also provides free national Polymerase Chain Reaction (PCR)-testing of clinical samples from patients with suspected IMD; Diagnostic laboratories are required by law to notify PHE when they identify *Neisseria meningitidis* and samples are requested to be sent to the MRU for confirmation and characterisation. PHE routinely reconciles laboratory-confirmed cases to generate a national dataset [12] and follows up each case for demographic data, vaccination history, clinical presentation and outcomes through Health Protection Teams (HPTs), general practitioners and, for younger cases, hospital clinicians. Details documented on HPZone (a web-based software for public health management of infectious diseases used by HPTs throughout England), were also accessed by PHE to obtain additional information on cases since 2010.

**Vaccine effectiveness**

Using the national dataset, MCC VE was calculated using the screening method [13] for confirmed MenC cases among MCC-eligible individuals (born since 1 September 1981) in England between 01 January 2000 and 30 June 2016. VE was estimated according to time since vaccination (or, if unvaccinated, since the age at last scheduled dose); analysis included unvaccinated children, those who had completed the recommended primary immunisation course for their birth cohort (three doses for those aged 1 year of less before September 2006), or had received one dose after their first birthday at any age. Effectiveness of the primary plus booster dose was based on cases who had received ≥ 1 primary MCC dose followed by the 12-month Hib/MCC booster. The following formula was used:

\[
VE = 1 - \frac{[PCV(1 - PPV)]}{[1 - PCV]PPV}
\]

Where PCV is the proportion of vaccinated MenC cases and PPV is the proportion of vaccinated population (i.e. vaccine coverage, matched to each case based on their age and birth cohort and then averaged). Annual national vaccine coverage by 12 months of age (from April 2001) and by 24 months of age (from April 2002) was used for the latter [14].

Data extracted in May 2016 from The Health Improvement Network (THIN) database [15] for children born from August 1999 to May 2015 was used to estimate partial vaccination proportions for each of the routine schedules (3 + 0, 2 + 1, 1 + 1) by 12 months.
and 24 months of age. These estimates of partial vaccination were used to adjust the national coverage estimates to give coverage in those who received either no vaccination or the full schedule. For example, it was estimated that in the three-dose primary cohort, 5.5% received one or two doses by 12 months, so national coverage of 90% for three doses would be adjusted to \( \frac{90 \times 100}{100 - 5.5} = 95.2\% \), once partial vaccination is excluded.

### Molecular characterisation

Typing data and genomes were obtained from the PubMLST Neisseria database and Meningitis Research Foundation (MRF) Meningococcus Genome Library (MGL), to which all MRU isolates from the national dataset have been referred since July 2010 [16,17]. A recent phylogenetic network analysis of the known population structure of MenC-associated cc11 sublineages was re-annotated in the context of the current study since cc11 represented the majority of recent invasive MenC isolates in England [18]. Briefly, all available global cc11 genomes, including 121/122 invasive MenC isolates from England (2010/11–2015/16), and excluding serogroup W-associated lineage 11.1 sublineages (final n = 898 globally; accessed 7 October 16), and two non-cc11 reference genomes (IDs 27778 and 29645; ccs 41/44 and 8, respectively), underwent core genome comparisons (1546 loci) using the PubMLST genome comparator tool. The resulting distance matrices were visualised using SplitsTree4. The invasive MenC cc11 isolates collected in England during 2010/11–2015/16 (inclusive) were highlighted [19].

### Serosurvey

Serum samples collected in 2014 were obtained from the PHE Seroepidemiology Unit; a depository of anonymised residual sera from routine diagnostic testing at participating laboratories. Known immunocompromised individuals are excluded from the collection. The age, sex and year of collection were known for individual samples: immunisation status was not known [20].

Serum bactericidal antibody (SBA) assays were performed against the serogroup C target strain, C11 (phenotype C:16: P1.7–1,1) as previously described [21]. The complement source used in the SBA was pooled serum from 3–4 week old rabbits (Pel Freez Biologicals, Arkansas, United States (US)). Titres were expressed as the reciprocal serum dilutions yielding ≥ 50% killing after 60 minutes. The lower limit of detection was a titre of 4. Titres of < 4 were assigned a value of two for geometric mean titre (GMT) analysis. Titres of ≥ 8 were considered protective against MenC disease [22].

Approximately 100 samples were selected from each age-band to fit with different vaccine schedules since MCC introduction and to allow comparison with previous studies. This sample size was selected to achieve reasonable precision around the 95% confidence intervals (CIs) for proportions with SBA titres ≥ 8 and GMTs within the age group of interest.

Since MCC vaccine coverage has been consistently high, the age of the serum donor was used to align the donor with the MenC vaccine schedule they should have been offered and thereby identify which MenC vaccine cohort they belonged to. This then allowed comparison of protection between schedules and over time, using historical data from three previously published similarly designed surveys. These earlier surveys used sera collected from the same Seroepidemiology Unit and tested using the same methodology in the same PHE laboratory during 1996–1999 [8], 2000–2004 [9] and 2009 [10].

---

### Table 1

Total number of confirmed group C meningococcal disease cases, England, 2006/17–2015/16 (N = 268)

| Epidemiological year | Age group (years) | <1 | 1–4 | 5–9 | 10–14 | 15–19 | 20–24 | 25–44 | 45–64 | ≥65 | Total |
|----------------------|------------------|----|-----|-----|-------|-------|-------|-------|-------|-----|-------|
| 2006/07              |                  | 2  | 2   | 2   | 0     | 1     | 3     | 7     | 7     | 4   | 28    |
| 2007/08              |                  | 1  | 2   | 1   | 0     | 4     | 2     | 7     | 4     | 7   | 28    |
| 2008/09              |                  | 0  | 1   | 1   | 2     | 0     | 0     | 1     | 7     | 1   | 13    |
| 2009/10              |                  | 1  | 4   | 3   | 1     | 1     | 0     | 5     | 2     | 0   | 17    |
| 2010/11              |                  | 2  | 3   | 2   | 1     | 1     | 0     | 6     | 4     | 3   | 22    |
| 2011/12              |                  | 3  | 3   | 2   | 1     | 1     | 0     | 6     | 4     | 3   | 29    |
| 2012/13              |                  | 0  | 1   | 1   | 4     | 3     | 3     | 9     | 7     | 5   | 33    |
| 2013/14              |                  | 1  | 2   | 5   | 2     | 0     | 1     | 7     | 6     | 3   | 27    |
| 2014/15              |                  | 1  | 0   | 6   | 0     | 3     | 0     | 10    | 7     | 2   | 29    |
| 2015/16              |                  | 1  | 1   | 4   | 3     | 3     | 1     | 13    | 7     | 9   | 42    |
| Total                |                  | 12 | 19  | 27  | 14    | 19    | 12    | 73    | 55    | 37  | 268   |
The London region, where 16% of the English population confirmed and 18 died (case fatality rate (CFR), 11%). Between 2011/12 and 2015/16, 160 MenC cases were sustained population protection effect. 2015/16 (n = 16) than 1998/99 (n = 111) consistent with a over (who were not vaccine eligible) were 86% lower in the same period. Cases in those aged 45 years and from 11% (0.09/100,000) to 4% (0.05/100,000) over the proportion of cases among 1–4 year-olds declined 17% between 2011/12–2015/16 (0.09/100,000), while 12% between 2006/07–2010/11 (0.04/100,000) to of cases among those aged 5–14 years increased from relatively constant (Figure 1). However, the proportion of cases among those aged 5–14 years increased from 12% between 2006/07–2010/11 (0.04/100,000) to 17% between 2011/12–2015/16 (0.09/100,000), while the proportion of cases among 1–4 year-olds declined from 11% (0.09/100,000) to 4% (0.05/100,000) over the same period. Cases in those aged 45 years and over (who were not vaccine eligible) were 86% lower in 2015/16 (n = 16) than 1998/99 (n = 111) consistent with a sustained population protection effect.

Of the 160 cases, 11 (7%) were living in shared accommodation (three university students, four in care homes or assisted living, four in house share or hostel accommodation). There were six cases in known men who have sex with men (MSM) and eight individuals reported using recreational drugs, were injecting drug users or had alcohol dependency. Nineteen cases (12%) had underlying co-morbidities; heart condition (n = 3), diabetes (n = 2), HIV (n = 6), immunosuppression (two on psoriasis treatment, one with chronic lymphocytic leukaemia, one post liver transplant), chronic respiratory condition (n = 3), liver disease (n = 3). There were three clusters of two cases each in primary schools nationally in 2015; all six children were fully-vaccinated (two-dose primary course with booster).

Vaccine effectiveness
Between 1 January 2000 and 30 June 2016, there were 316 MenC cases in vaccine-eligible individuals, of whom 119 had been fully-vaccinated according to their recommended schedule (Table 2). Estimated VE within 12 months of immunisation at all targeted ages (including infants) was high at 91% to 96%. Following routine infant vaccination or a single dose administered to cohorts aged 1 to 4 years when the catch-up programme began, a trend for lower VE with increasing time since vaccination was observed (p = 0.009 and p = 0.03 respectively) (Table 2). In school-aged cohorts (aged 5–18 years when immunised), high VE was sustained over time, remaining at 95.0% (95% CI: 76.0 to 99.5%) at least 8 years after vaccination. Of the 26 cases eligible for the Hib/MenC booster, 25 were vaccinated, with matched coverage of 94.6%; VE was -43% but with wide confidence intervals (95% CI: -5,759 to 77). This calculation is very sensitive to the number of unvaccinated cases; for example, the addition of just two unvaccinated cases would change this estimate to 52%.

Molecular characterisation
During 2010/11–2015/16, there were 182 laboratory-confirmed MenC cases in England’s national dataset, of which 122 were culture-confirmed. Molecular characterisation was available for 121 isolates, 89 of which (73.6%) belonged to the ST-11 clonal complex (cc11); ranging from 4 of 12 in 2010/11 to 27 of 30 in 2015/16. Other clonal complexes included cc103 (n = 9), cc269 (n = 6), cc-unassigned (n = 5), cc32 (n = 3), cc41/44 (n = 3), cc174 (n = 2) and a single isolate each for cc116, cc23, cc334 and cc60 (Figure 2). The population structure of cc11 (minus the MenW-associated lineage 11.1 sublineages) [18] comprised two main lineages, lineage 11.1 (corresponding to ET-37; n = 245; 6 MenB, 229 MenC, 1 MenY and 9 serogroup unspecified) and lineage 11.2 (corresponding to ET-15; n = 649; 77 MenB, 536 MenC, 3 MenW and 33 non-groupable-serogroup unspecified) (Figure 3a).

The English cc11 case isolates from 2010/11 to 2015/16 belonged to both lineage 11.1 (n = 32; 36.0%) and

![Figure 1](www.eurosurveillance.org)
### Table 2

Meningococcal serogroup C conjugate vaccine effectiveness based on the screening method in immunised cohorts, England, September 2000–June 2016

| Cohort                      | Approximate age at MCC vaccine | Average matched population coverage | Proportion of cases vaccinated | Overall vaccine effectiveness % (95% CI) | Vaccine effectiveness based on time since vaccination % (95% CI) | Trend analysis* |
|-----------------------------|--------------------------------|-------------------------------------|-------------------------------|------------------------------------------|---------------------------------------------------------------|------------------|
|                            |                                | %                                  | n/N                           | Overall                                    | Within 1 year                                                |                  |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
| Routine infant**<sup>c,d</sup> (o or 3 doses only) | 2, 3, 4m                        | 95.9                                | 51/61                          | 83.6                                      | 78 (52 to 89)                                                | 94 (80 to 98)    |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
| Routine 2 + 1 schedule<sup>e</sup> (o or 3 doses only) | 2, 4, 12m                        | 94.6                                | 25/26                          | 96.2                                      | -43 (-5.759 to 77)                                           | too few cases    |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
| Infant catch-up (o or 2 doses only) | 5–11m                           | 80.2                                | 6/16                           | 37.5                                      | 85 (55 to 96)                                                | 91 (8 to 100)    |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
| Toddlers catch-up (o or 1 dose) | 1–2y                            | 80.2                                | 11/27                          | 40.7                                      | 83 (61 to 93)%                                              | 6 (87 to 99)     |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
| Pre-school catch-up (o or 1 dose) | 3–4y                            | 71.9                                | 7/47                           | 14.9                                      | 93 (85 to 97)                                                | 96 (87 to 99)    |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
| Infant school catch up (o or 1 dose) | 5–6y                            | 57.7                                | 3/23                           | 13.0                                      | 89 (63 to 98)                                                | 95 (88 to 98)    |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
| Junior school catch up (o or 1 dose) | 7–10y                           | 84.2                                | 3/10                           | 30.0                                      | 92 (65 to 99)                                                | 95 (90 to 96)    |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
| Secondary school catch-up (o or 1 dose) | 11–16y                          | 85.0                                | 8/55                           | 14.5                                      | 97 (94 to 99)                                                | 95 (90 to 96)    |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
| Sixth form catch-up<sup>f</sup> (o or 1 dose) | 17–18y                          | 60.1                                | 5/51                           | 9.8                                       | 93 (82 to 98)                                                | 96 (95 to 96)    |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
| Total                      |                                | All ages                           | NA                            | 119/316                                   | 37.7                                                        | NA               |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |
|                            |                                |                                     |                               |                                           | C1: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years. |

* Trend analysis was done by logistic regression for the odds of vaccination in cases against log-time since vaccination with an offset of the log-odds of matched coverage. The exception was for the infant catch-up, where time was modelled as within a year and beyond a year as numbers were too small to model a trend.

<sup>a</sup> Unvaccinated cases are based on the date of birth cohort each individual belongs to.

<sup>b</sup> Including cases from January 2000.

<sup>c</sup> Including one vaccinated case scheduled for three infant doses but only given a single dose after 12 months of age.

<sup>d</sup> Including cases from April 2006.

<sup>e</sup> Including cases from April 2000.
lineage 11.2 ($n = 57; 64.0\%$), where they mainly belonged to several closely-related clusters (Figure 3a). The predominant PorA subtypes were P1.5,2 (93.8\%) and P1.5–1,10–8 (96.5\%), respectively. Since 2010/11, the number of lineage 11.1-related cases increased from one to 10 per year, while the lineage 11.2-related cases varied between three (2010/11) and 17 (2015/16) (Figure 3b,c). Isolates from vaccine-failure cases were randomly distributed among the overall English MenC cc11 population (not shown).

**Serosurvey**

Results were available for 993 samples collected in 2014 and 323 (33\%; 95\% CI: 30.1 to 35.9) had SBA titres ≥ 8. The proportion of individuals achieving the seroprotective threshold was remarkably similar across the age groups in 2014 compared with 2009 (Figure 4). In contrast, much higher proportions of 5–19 year-olds were seroprotected during 2000–04, the period immediately after the 1999/2000 national catch-up for 0–18 year-olds. This cohort is now older and responsible for the secondary peak of seroprotection among 15–34 year-olds in subsequent serosurveys. Notably, only 38\% of 15–19 year-olds achieved the seroprotective threshold in 2014 compared with 56\% in 2009. Only 25\% (75/299) children aged 1–14 years were seroprotected against MenC in 2014.

The 14/15 year-olds and 16 year-olds were separated in 2014 because they received different primary vaccination (Table 3) and to maintain consistency with the 2009 survey. Analysis by birth cohort and eligible vaccine schedule indicated higher GMT (10.6; 95\% CI: 4 to 29 vs 3.7; 95\% CI: 2 to 6) and proportions with SBA titres ≥ 8 (28.2\%; 95\% CI: 15 to 44 vs 17.0\%; 95\% CI: 8 to 30) among 14–15 year-olds (the cohort eligible for the adolescent booster) in 2014 compared with 2009 (Table 3). In the younger age groups, GMTs and proportion protected were generally lower in 2014 compared with 2009 (Table 3).

**Discussion**

**Epidemiology**

MenC disease in England remains at very low levels with an incidence of 0.08/100,000 in 2015/16, an overall reduction of 95.6\% compared with 1998/99 before MCC vaccination was introduced. Nearly a third of cases are currently diagnosed in 25–44 year-old adults, many with clinical, social and travel-related risk factors. Overall case fatality remains unacceptably high. Updated VE estimates indicate a rapid decline in protection after 1 year following routine infant immunisation, but this remains high in children immunised at school age (5–18 year-olds) up to at least 8 years after vaccination.

The low MenC disease incidence is reassuring and is consistent with continued herd protection in the wider population and high direct protection in those who have been vaccinated. There have been no cases reported among at-risk individuals, currently defined as those with asplenia, splenic dysfunction or complement deficiency. Those born outside the UK (who are less likely to be immunised with MCC, even if eligible on entry), recently travelled and/or socially mixing with these populations accounted for a quarter of all cases, while a significant proportion of the other cases were living in shared or supported accommodation, which is a known risk factor for IMD [23]. An increased risk of IMD in HIV-positive individuals has recently been reported [24], even among those receiving appropriate antiretroviral therapy. Over the past 5 years, six HIV-positive individuals were identified among 160 MenC cases in England, all in the 25–44 year age group, including two who were non-UK born and had recently travelled abroad: Outbreaks of MenC disease in MSM populations have been reported in North America and Europe [25,26]. Whole genome sequencing previously showed that MenC case isolates among MSMs in England, while all belonging to lineage 11.2, were interspersed among sporadic community case isolates and did not form a discrete cluster [27].
Figure 3
Diversity and temporal distribution of meningococcal serogroup C case isolates, England, 2010/11–2015/16

A. Non-cc11 isolates

B. Cases due to lineage 11.1 isolates have increased since 2010/11, whilst C) cases due to lineage 11.2 isolates have fluctuated.

A) Neighbor-net phylogenetic network based on a comparison of 1,546 core genes among all available cc11 genomes on the PubMLST database, excluding predominantly-serogroup W lineage 11.1 sublineages (final n = 898; accessed 07/10/16). The English meningococcal serogroup C case isolates from 2010/11 to 2015/16 (red dots) were mainly distributed among several closely related lineage 11.1 and lineage 11.2 clusters, respectively.
**Figure 4**
Seroprotection against serogroup C meningococci measured by proportions with serum bactericidal antibody (SBA) titres of ≥ 8

---

SBA: serum bactericidal antibody.

Comparison of levels in 2014 with the previous surveys conducted before MenC conjugate vaccine introduction in 1996–99 and following introduction in 2000–04 and 2009.

---

**Molecular characterisation**

Recent MenC cases in England were caused by diverse meningococcal strains, representing at least 10 different clonal complexes over the past 6 years. Most cases, however, were caused by two diversifying cc11 strains, one each from the two recently-resolved major cc11 lineages (lineages 11.1 and 11.2) [27,28]. Our findings warrant continued close monitoring, as lineage 11.1 cases have increased steadily over the past 6 years, while 2015/16 also saw the greatest number of lineage 11.2 cases. In addition to high case fatality rates for cc11 in general, the presence of lineage 11.2 isolates is concerning for several reasons. Evidence of frequent MenB to MenC capsule switching is coupled with poor potential coverage by, and the ability to escape from, several existing and experimental MenB vaccines [18]. Furthermore, distinct lineage 11.2 populations have independently acquired traits that may facilitate urogenital colonisation [29,30]. The acquisition of intact aniA alleles encoding nitrite reductase may enable survival in microanaerobic environments and has been associated with outbreaks of invasive disease among MSM in the US and Europe [30-32] and urethritis among heterosexual males in the US [29,30]. The urethritis-associated strain has also lost its ability to express a capsule, a further gonococcal trait that may facilitate adherence to the urogenital mucosa.

**Serosurvey**

Seroprevalence studies have proven valuable in improving our understanding of population immunity, inform mathematical modelling and can complement disease surveillance to help inform national vaccine policy [8-10]. The 2014 serosurvey confirmed the rapid decline in immunity after infant and toddler immunisation (also observed with the 2009 serosurvey) as well as the low proportion of teenagers protected against MenC disease around the time when the adolescent programme was introduced. Similar trends have been reported in the Netherlands, where a large catch-up campaign targeting 1–19 year-olds in 2002 was followed by routine childhood immunisation at 14 months of age only. Here, a recent serosurvey found only 19% of 10 year-olds were protected 9 years after a single MCC dose at 14 months [33]. The successful control of MenC disease in the UK is attributed to the large catch-up campaign in 1999/2000. Teenagers and young adults have the highest nasopharyngeal meningococcal carriage rates and are considered the main source of spread. MCC vaccines not only protect against invasive disease but also against nasopharyngeal acquisition, thereby inducing herd protection across all age groups [4,6]. The current cohort of younger children with poor seroprotection is most likely protected against disease because of this indirect protection.

Most adolescents in 2014 will have received a three-dose infant MCC schedule without a booster. The low proportion of teenagers achieving protective antibody thresholds in the 2014 serosurvey indicated there was poor long-term direct protection in the cohort that was only immunised in infancy and ongoing herd protection across the population could be threatened. This observation, predicted after the 2009 serosurvey, helped support the inclusion of MCC in the adolescent programme in 2013 with the aim of providing high antibody concentrations throughout the peak years of carriage [7]. The 2014 serosurvey is already demonstrating higher MCC antibodies among 14–16 year-olds compared with the same age group in the previous serosurvey. The emergency adolescent MenACWY programme in 2015 was implemented to provide direct and indirect protection, not only against MenC but also against nasopharyngeal acquisition, thereby inducing herd protection across all age groups [7]. The current cohort of younger children with poor seroprotection is most likely protected against disease because of this indirect protection.

---

**Implications for other countries**

In Europe, MenC disease incidence is currently low (<1/100,000) in countries with and without routine MCC vaccination [3]. Disease in infants remains rare and thus in countries with routine MCC immunisation most cases occur in adults, with a median age of 41 years compared with 22 in countries without MCC vaccination programmes. The recent increase in MenC cases in France highlights the importance of maintaining high vaccine coverage, especially in adolescents, in order to sustain long-term direct and indirect disease control.
A number of countries across Africa, Latin America and elsewhere are also experiencing high MenC disease activity [35,36]. Travellers to such countries, including residents visiting family and friends in their home countries, should be appropriately immunised, advised to avoid high-risk behaviours, remain vigilant for symptoms and signs of meningococcal disease and seek immediate medical help if concerned while abroad and when returning to their home countries.

Strengths and limitations

The strength of this study is the consistently high quality of the national surveillance programme with high case ascertainment [12] and active follow-up of cases since 1998/99. This has allowed us to monitor VE in different cohorts over time. Our meningococcal surveillance is complemented with clinical trials, to assess the immunogenicity of different schedules, and serosurveys to monitor population susceptibility. Together, these results have allowed us to adapt the national immunisation programme to provide maximal long-term protection in the most cost-efficient manner. Using the same methodology allows us to monitor population effects over time. A limitation of the serosurvey, however, is that we have no information on the vaccination status of the serum donors or their clinical state. Nonetheless, the large numbers of samples tested, along with the consistently high vaccine coverage nationally has allowed us to analyse the results by birth-cohorts.

Conclusions

We found evidence for rapid waning of immunity following routine infant immunisation, even with a 12-month booster, which was introduced in 2006. Currently, most toddlers (1-4 years) and older children (aged 5-13 years) in England are not seroprotected against MenC disease and are dependent on the indirect protection offered through reduced carriage in young people aged 17-24 years. It is, therefore, reassuring that there is still evidence of herd protection in adults 17 years after mass vaccination of children in 1999. Immunisation of teenagers appears to be key for continued population impact, but also for direct protection before their social behaviour leads to greater exposure, carriage and invasive disease. We have demonstrated high short-term effectiveness of MCC vaccines in infants and preschool children and the long-term effectiveness of MCC vaccines in teenagers, although with some waning over the following 5 years. Continued surveillance of VE and vaccination coverage is essential in order to ensure that the highest levels of protection are maintained. As the populations of teenagers and adults are at the highest risk of meningococcal disease, it is important to continue to monitor the herd immunity in these age groups and adjust the vaccination policy when appropriate.
vaccines given to school-aged children and adolescents. These findings have led to several revisions of the UK immunisation schedule to maximise direct and indirect protection. The recent change to emergency MenACWY vaccination for teenagers was brought in to provide more rapid population control for the national MenW outbreak. It should also provide continued direct and population control for MenC and help establish this for MenY disease.

Continued epidemiological and microbiological surveillance will be critical to monitor current programmes which now include newer sub-capsular protein-based vaccines against MenB disease in infants. MenC disease continues to be rare but detailed case-based follow-up has identified certain groups that remain at higher risk for MenC disease despite containment within the wider population, these groups may benefit from targeted vaccination. Stochastic meningococcal outbreaks globally need to be carefully monitored, as well as the recent MenC outbreaks among MSM. High-resolution characterisation is critical to monitor circulating strains and detect known and unknown emerging threats.

Acknowledgements

We thank all laboratory staff at Public Health England Meningococcal Reference Unit and Public Health England Immunisation Team staff for their assistance with all work related to the enhanced surveillance of invasive meningococcal disease in the UK together with colleagues in Health Protection Teams and general practice. This publication made use of the Neisseria Multi Locus Sequence Typing website (https://pubmlst.org/neisseria/) developed by Keith Jolley and sited at the University of Oxford (Jolley & Maiden 2010, BMC Bioinformatics, 11:595). The development of this site has been funded by the Wellcome Trust and European Union. The publication also made use of the Meningitis Research Foundation Meningococcus Genome Library (http://www.meningitis.org/research/genome) developed by Public Health England, the Wellcome Trust Sanger Institute and the University of Oxford as a collaboration and part-funded by the Meningitis Research Foundation.

Conflict of interest

None declared.

Authors’ contributions

The concept of the paper was generated by RB, SL and HC with a first draft written by HF and all authors contributing to the final manuscript. Epidemiological analysis was undertaken by HC, analysis of the seroepidemiological data was undertaken by HF, statistical analysis was undertaken by NA and molecular characterisation by JL.

References

1. Sáfadi MA, Bettinger JA, Maturana GM, Enwere G, Borrow R. Global Meningococcal Initiative. Evolving meningococcal immunization strategies. Expert Rev Vaccines. 2015;14(4):505-17. https://doi.org/10.1586/14766054.2015.979799 PMID: 25496168

2. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58-67. https://doi.org/10.1016/S0264-410X(01)00299-7 PMID: 11587814

3. Whittaker R, Dias JG, Ramldien M, Ködmön C, Economopoulou A, Beer N, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017;35(16):2034-41. https://doi.org/10.1016/j.vaccine.2017.03.007 PMID: 28314560

4. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365-6. https://doi.org/10.1136/bmj.326.7385.365 PMID: 12586669

5. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840-7. https://doi.org/10.1128/CVI.00299-09 PMID: 20219881

6. Maiden MC, Stuart JM. Meningococcal Carriage Group. Circulation of serogroup C meningococcal disease in the UK: meningococcal C conjugate polysaccharide vaccine. Lancet. 2002;359(9320):1829-31. https://doi.org/10.1016/S0140-6736(02)02867-8 PMID: 12044380

7. Ladhani SN, Ramsay M, Borrow R, Riordan A, Watson JM, Pollard AJ, Enter B and W: two new meningococcal vaccine programmes launched. Arch Dis Child. 2016;101(1):91-5. https://doi.org/10.1136/archdischild-2015-308928 PMID: 26627098

8. Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup B bacterial antibody in England and Wales in the pre-vaccination era. Vaccine. 2003;21(11-12):1094-8. https://doi.org/10.1016/S0264-410X(02)00630-8 PMID: 12559785

9. Trotter CL, Borrow R, Findlow J, Holland A, Frankland S, Andrews NJ, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the post-vaccination era. Clin Vaccine Immunol. 2008;15(1):1694-8. https://doi.org/10.1128/CVI.00279-08 PMID: 18827191

10. Ishola DA Jr, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol. 2012;19(8):1126-30. https://doi.org/10.1128/CVI.00655-11 PMID: 22647271

11. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006;55(7):887-96. https://doi.org/10.1099/jmm.0.46288-0 PMID: 16772416

12. Ladhani SN, Waigt PA, Ribeiro S, Ramsay ME. Invasive meningococcal disease in England: assessing disease burden through linkage of multiple national data sources. BMC Infect Dis. 2015;15(1):551. https://doi.org/10.1186/s12879-015-1247-7 PMID: 26626321

13. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22(4):742-6. https://doi.org/10.1093/ije/22.4.742 PMID: 8225751

14. National Health Service (NHS) digital. Statistics and data collections. Available from: https://digital.nhs.uk/data-and-information

15. The Health Improvement Network (THIN). London: THIN; 2018. Available from: http://www.inps.co.uk/visibility/thin/about-us

16. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics. 2010;11(1):595. https://doi.org/10.1186/1471-2105-11-595 PMID: 21143983

17. Hill DM, Lucidarme J, Gray SJ, Newbold LS, Ure R, Brehony C, et al. Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study. Lancet Infect Dis. 2015;15(11):1269-78. https://doi.org/10.1016/S1473-3099(15)00267-4 PMID: 26551523

18. Lucidarme J, Leksmi A, Parikh SR, Bray JE, Hill DM, Bratcher HB, et al. Frequent capsule switching in ‘ultra-virulent’ meningococci - Are we ready for a serogroup B ST-11 complex outbreak? J Infect. 2017;75(2):95-103. https://doi.org/10.1016/j.jinf.2017.05.015 PMID: 28579305

19. Huson DH. SplitsTree: analyzing and visualizing evolutionary data. Bioinformatics. 1998;14(1):68-73. https://doi.org/10.1093/bioinformatics/14.1.68 PMID: 9520593

20. Osborne K, Gay N, Hesketh L, Morgan-Capan P, Miller E. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol.
21. Maslanka SE, GheeSSLing LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al. The Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol. 1997;4(2):156-67. PMID: 9067649

22. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005;23(17-18):2222-7. https://doi.org/10.1016/j.vaccine.2005.01.051 PMID: 15755600

23. Neal KR, Nguyen-Van-Tam J, Monk P, O’Brien SJ, Stuart J, Ramsay ME, et al. Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study. BMC Med. 2015;13(1):297. https://doi.org/10.1186/s12916-015-0538-6 PMID: 26654248

24. Folaranmi TA, Kretz CB, Kamiya H, MacNeil JR, Whaley MJ, Blain A, et al. Increased Risk for Meningococcal Disease Among Men Who Have Sex With Men in the United States, 2012-2015. Clin Infect Dis. 2017;65(5):756-63. https://doi.org/10.1093/cid/cix38 PMID: 28505234

25. Lucidarme J, Hill DM, Bratcher HB, Gray SJ, du Plessis M, Tsang RS, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect. 2015;71(5):544-52. https://doi.org/10.1016/j.jinf.2015.07.007 PMID: 26226598

26. Taha MK, Claus H, Lappann M, Veyrier FJ, Otto A, Becher D, et al. Evolutionary events associated with an outbreak of meningococcal disease in men who have sex with men. PLoS One. 2016;11(5):e0154047. https://doi.org/10.1371/journal.pone.0154047 PMID: 27167067

27. World Health Organisation (WHO). Continuing risk of meningitis due to Neisseria meningitidis serogroup C in Africa: revised recommendations from a WHO expert consultation. Wkly Epidemiol Rec. 2017;92(41):612-7. PMID: 29028166

28. Nunes AM, Ribeiro GS, Ferreira ÍE, Moura AR, Felzemburgh RD, de Lemos AP, et al. Meningococcal Carriage among Adolescents after Mass Meningococcal C Conjugate Vaccination Campaigns in Salvador, Brazil. PLoS One. 2016;11(1):e0166475. https://doi.org/10.1371/journal.pone.0166475 PMID: 27861618